Market Overview

Synta Announces Termination for Futility of Ganetespib Phase 3 GALAXY-2 Trial in Lung Cancer


Synta Pharmaceuticals Corp. (NASDAQ: SNTA) today announced that the
Company has decided to terminate the Phase 3 GALAXY-2 trial of
ganetespib and docetaxel in the second-line treatment of patients with
advanced non-small cell lung adenocarcinoma. Based on the review of a
pre-planned interim analysis, the study's Independent Data Monitoring
Committee (IDMC) concluded that the addition of ganetespib to docetaxel
is unlikely to demonstrate a statistically significant improvement in
the primary endpoint of overall survival compared to docetaxel alone.
The IDMC noted that the combination of ganetespib and docetaxel was
generally well tolerated in the study, with an adverse event profile
consistent with previous studies combining these agents.

GALAXY-2 is a Phase 3 global, randomized, multi-center

See full press release

Posted-In: News FDA Press Releases


Related Articles (SNTA)

View Comments and Join the Discussion!

Benzinga's M&A Chatter for Tuesday October 20, 2015

Renasant Corporation, KeyWorth Bank Announce Definitive Merger Agreement Valued @~$58.7M